Clinical Trial Update: Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating Fuzheng Huayu plus Entecavir for low-grade cirrhotic portal hypertension due to hepatitis B virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease Related to Hepatitis Virus Infection
• Portal Hypertension

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Fuzheng Huayu

Snippet

Sponsor: ShuGuang Hospital | Conditions: Portal Hypertension | Phase 4 | Status: UNKNOWN